Savara Inc. Aktie
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | -3,03 % | -5,88 % | -6,73 % | 152,12 % | -2,80 % | 163,29 % | -56,36 % |
Gritstone Oncology Inc | -0,33 % | -1,83 % | -69,33 % | -65,20 % | -59,63 % | -90,01 % | - |
Avid Bioservices Inc | 0,70 % | 13,49 % | 11,72 % | -54,17 % | 17,21 % | -59,60 % | 68,99 % |
Pacira Pharmaceuticals | 0,83 % | 1,68 % | -7,63 % | -39,20 % | -18,79 % | -53,01 % | -30,82 % |
Kommentare
News
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending